Nmi Antibody (XX-22): sc-101100
- Nmi Antibody (XX-22) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant Nmi of human origin
- recommended for detection of Nmi of human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Nmi Antibody (XX-22). This work is in progress.
QUICK LINKS
SEE ALSO...
Nmi Antibody (XX-22) is a mouse monoclonal IgG2b antibody that detects Nmi in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Nmi, or N-Myc interactor, plays a crucial role in cellular signaling and transcriptional regulation, particularly in myeloid leukemias and other cancers where Nmi is often overexpressed. Nmi is primarily located in the nucleus, where Nmi interacts with several key transcription factors, including c-Myc, n-Myc, and members of the Stat family, thereby influencing gene expression in response to cytokine stimulation. Nuclear localization of Nmi is vital as Nmi allows for direct modulation of transcriptional activity, enhancing the function of Stat proteins by recruiting essential coactivators such as CREB-binding protein (CBP) and p300. This recruitment significantly increases transcriptional responsiveness of Stat proteins, particularly Stat5, to interleukin-2 stimulation, underscoring Nmi′s importance in regulating immune responses and cellular growth. With an ability to enhance transcriptional activity despite lacking intrinsic DNA binding capabilities, Nmi serves as a critical mediator in signaling pathways that govern cell proliferation and differentiation, making Nmi a valuable target for research in cancer biology and therapeutic development.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Nmi Antibody (XX-22) References:
- A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. | Li, H., et al. 2002. J Biol Chem. 277: 20965-73. PMID: 11916966
- Nmi (N-Myc interactor) inhibits Wnt/beta-catenin signaling and retards tumor growth. | Fillmore, RA., et al. 2009. Int J Cancer. 125: 556-64. PMID: 19358268
- Pregnancy and interferon tau regulate N-myc interactor in the ovine uterus. | Song, G., et al. 2011. Domest Anim Endocrinol. 40: 87-97. PMID: 21067885
- Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling. | Devine, DJ., et al. 2014. Oncogene. 33: 2620-8. PMID: 23770854
- N-Myc interactor inhibits prototype foamy virus by sequestering viral Tas protein in the cytoplasm. | Hu, X., et al. 2014. J Virol. 88: 7036-44. PMID: 24719420
- microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer. | Rostas, JW., et al. 2014. Mol Cancer. 13: 200. PMID: 25174825
- N-Myc-interacting protein (NMI) negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of NF-κB/p65. | Hou, J., et al. 2016. Cancer Lett. 376: 22-33. PMID: 27012186
- NMI promotes cell proliferation through TGFβ/Smad pathway by upregulating STAT1 in colorectal cancer. | Ji, D., et al. 2020. J Cell Physiol. 235: 429-441. PMID: 31230364
- Downregulation of N-myc Interactor Promotes Cervical Cancer Cells Growth by Activating Stat3 Signaling. | Wu, S., et al. 2021. Cell Biochem Biophys. 79: 103-111. PMID: 33106998
- N-myc-interactor mediates microbiome induced epithelial to mesenchymal transition and is associated with chronic lung allograft dysfunction. | Banday, MM., et al. 2021. J Heart Lung Transplant. 40: 447-457. PMID: 33781665
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nmi Antibody (XX-22) | sc-101100 | 100 µg/ml | $333.00 |